Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic
  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Week in Review: Zai Lab Announces Two In-Licensings with Total Value of $800 Million

Deals and Financings   Shanghai Zai Lab announced two in-licensings: a $615 million deal for two cancer drugs from Blueprint and a $187 million agreement for a Karuna psychiatric drug; I-Mab formed a $315 million collaboration with Hubei Jumpcan Pharma to commercialize I-Mab's human growth hormone in  China ; Arbor Biotech, a  Cambridge   MA  gene editing company, raised $215 million in an oversubscribed B round led by Temasek and Ally   Bridge ; Shanghai 's Ignis Therapeutics, which was spun out from  South Korea 's SK Biopharma, raised an initial $180 million to bring SK's CNS drug assets to  China ; Hopstem Biotech, a China-US stem-cell therapy company, completed a near $40 million B financing from Lilly Asia Ventures and YuanBio Venture Capital; Hangzhou 's Ascletis Pharma extended its viral disease partnership for Alphamab's PD-L1 to include global rights;  Trials and Approvals   Everest Medicines said its novel TROP-2 antibody-drug conjugate met its primary endpoint in a China Phase II trial in triple-negative breast cancer patients; Ascletis Pharma of  Hangzhou  was approved to start a China Phase II clinical trial of its PD-L1 candidate in HIV-1 patients as a possible cure of HIV-1; Gmax Biopharm, a novel  Hangzhou  antibody company focused on GPCRs, has begun a China Phase I trial of its obesity therapy; Nanjing IASO Bio dosed the first patient in a China Phase I/II trial of its fully human CD19/CD22 CAR-T cell therapy for non-Hodgkin's lymphoma.  Stock Symbols: (NSDQ: ZLAB; HKEX: 9688) (NSDQ: KRTX) (NSDQ: IMAB) (SHA: 600566) (HK; 1672) (HK 1952) (HK: 1672) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.